Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
Hosted on MSN1mon
Ozempic-like jab 'fails' for millions with condition, study findsExperts had hoped a medication called exenatide, a weight loss jab in the same class of drugs as Ozempic and Wegovy, could help combat the degenerative nerve condition. But University College of ...
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
GlobalData on MSN11d
Vivani treats first patient with long-lasting drug implant for weight lossThe device, dubbed NPM-115, is a miniature sub-dermal implant that delivers exenatide, a glucagon-like peptide-1 receptor ...
Hosted on MSN3mon
Vivani begins exenatide implant trial for obesity in AustraliaVivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to assess the pharmacokinetic and safety profile of its exenatide NanoPortal ...
Exenatide ext-rel 2mg; susp for SC inj; contains sucrose. Exenatide activates the GLP-1 receptor, thereby increasing intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback